Horizon Pharma plc Announces Collaboration With Alliance for Lupus Research to Study RAYOS(R) (prednisone) Delayed-Release Tablets in Systemic Lupus Erythematosus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Linden Disruption Expected to Have 'Minimal Impact' on Horizon Pharma (HZNP) - Mizuho
November 11, 2015 11:57 AM ESTMizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they expect minimal impact from Linden disruption.
Koffler commented, "We spoke with management and learned that Linden processes ~150-200 prescriptions for Duexis, Vimovo, Pennsaid, and... More
Horizon Pharma (HZNP) Enteres Collaboration with ALR for RAYOS Study in SLE
November 11, 2015 7:05 AM ESTHorizon Pharma (NASDAQ: HZNP) announced a collaboration with the Alliance for Lupus Research (ALR) to study RAYOS (prednisone) delayed-release tablets in systemic lupus erythematosus (SLE), a chronic autoimmune disease that causes inflammation and pain in the joints and muscles as well as overall fatigue.
"Despite advances in SLE therapies, sustained control of disease activity is limited to a small fraction of patients," said Jeffrey D. Kent, M.D., FACG, senior vice president, medical affairs and outcomes research, Horizon Pharma plc. "Prednisone is the steroid most commonly prescribed for lupus and given the unique... More
